ANI Pharmaceuticals’ (ANIP) Buy Rating Reiterated at Guggenheim

Guggenheim reissued their buy rating on shares of ANI Pharmaceuticals (NASDAQ:ANIP – Free Report) in a research report report published on Friday,Benzinga reports. Guggenheim currently has a $86.00 target price on the specialty pharmaceutical company’s stock. A number of other research analysts also recently commented on the stock. StockNews.com downgraded shares of ANI Pharmaceuticals from […]